Abstract

Background: EGFR mutational testing is crucial for advanced non-squamous NSCLC. PAP is a sensitive and selective method to detect rare mutations.
Methods: Eighty-five patients with non-squamous NSCLC were enrolled in this study. A set of paired plasma samples from each patient were collected and detected by PAP and ARMS.
Results: Of 85 paired samples, 78.8% (67/85) presented the same mutational status by the two methods. There was no statistically significant difference between the mutation frequencies in plasma samples detected with PAP and ARMS (p = 0.096).
Conclusions: PAP technology appears to be an alternative choice with relatively high sensitivity for the detection of plasma EGFR mutations.

DOI: 10.7754/Clin.Lab.2019.190216